Navigation Links
REGURIN(R) XL (trospium chloride) Once Daily Tablets Now Available in the UK for the Treatment of Overactive Bladder

LONDON, September 7 /PRNewswire/ -- Regurin(R) XL (trospium chloride), a once-daily, prolonged-release capsule to treat patients with overactive bladder (OAB) has been launched in the UK. Regurin(R) XL provides rapid, significant and consistent improvements in the symptoms of OAB1 and has a reduced potential for central nervous system (CNS) side effects(2-7).

OAB, also known as irritable bladder, is a condition that results from sudden, involuntary contraction of the muscle in the wall of the urinary bladder. Key symptoms of OAB include frequent urination, urgency of urination, and urge incontinence. Urinary incontinence is a distressing and often embarrassing problem estimated to affect over a third of women in the UK over 40(8).

By rapidly, significantly and consistently improving the symptoms of OAB as early as day 5 of treatment., a statistically significantly higher number of patients in placebo controlled clinical trials achieved a reduction in urgency and wet days by week 12 with Regurin(R) XL (1). Furthermore, Regurin(R) XL has the benefit of not crossing the blood- brain barrier, or the blood eye barrier(2,4,7) reducing the CNS side effects sometimes associated with OAB treatments(2-7).

"Overactive bladder has a significant, and often underestimated, impact on the quality of life of all patients. In elderly dependent patients OAB can cause breakdown in care-giving relationships and even increase the likelihood of patients being admitted to a nursing home , said Professor Linda Cardozo, Kings College Hospital, London. "It is important to effectively treat OAB, to maintain confidence and independence in all patients. Ensuring patient compliance is an important consideration in treating patients with OAB. Therefore, the availability of cost effective, tried and tested treatment, with the convenience of once-daily dosing, and minimal side effects is welcome news for physicians and their patients".

Clinical trials showed the incidence of dry mouth, and constipation also occurs less frequently in patients on Regurin(R) XL compared to all other antimuscarinic agents, and approximately 50% less than Regurin(R) 20mg twice daily(9,10). In addition, Regurin(R) XL has a low potential for interaction with concomitantly administered medications.(11- 13).

Geoff McMillan, Chief Executive Officer of SEP, said: "As a young Company with a focus on Urology, the launch of Regurin XL is very exciting. Urinary incontinence is a very common and embarrassing problem and we believe that Regurin XL offers significant benefits for patients, their physicians and the health service as a whole."

Regurin(R) XL is licensed for use in men and women to treat the symptoms of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with OAB.

Exclusive distribution rights in the UK for Regurin(R) XL (trospium chloride), have been granted to Specialty European Pharma Ltd (SEP), a UK based, urology focused, specialty pharmaceutical company by Rottapharm|Madaus.

About Regurin(R) XL

Regurin is trospium chloride, a member of the anti-muscarinic class, used to treat the symptoms of OAB. The efficacy has been well established. Trospium chloride has been recommended by NICE for the second line treatment of UI in women after immediate release oxybutynin(14). Regurin XL has a high selectivity for two receptors in the detrusor muscle, M sub(2) and M sub(3)(15).

Regurin(R) XL is a quaternary amine: as such it is a positively charged molecule that does not cross the blood brain barrier or the blood eye barrier(2,4,7) hence unwanted side effects such as impairment of cognitive function are minimal2-7 - an important consideration especially for the elderly population.

    About Speciality European Pharma

Founded in April 2006, SEP is a privately owned speciality pharmaceutical company. Its mission is to become the leading Urologist focused specialty pharmaceutical business in Europe.

SEP owns worldwide rights to Plenaxis(R). Plenaxis is a novel product - it is the first in a new class of hormonal products (the GnRH blockers) and it is used to treat advanced and metastatic prostate cancer. Plenaxis has been launched in Germany and is going through the regulatory process in other EU countries.

SEP has distribution rights in certain European countries for two further products, Amphocil(R), an antifungal agent and Haemopressin(R), a product for the treatment of Bleeding Oesophageal Varices. Both of these products are delivered to clinicians in a hospital setting.

SEP has established its own commercial operations in the UK, Germany, France and Italy and will market its products in other regions and territories through relationships with expert partners.

About Rottapharm|Madaus

Established in 1961, Rottapharm is a multinational pharmaceutical company primarily engaged in the research, development and global distribution of new pharmaceutical products in different therapeutic areas including rheumatology, cardiology, gastroenterology, gynaecology paediatrics, dermatology, urology, oncology, bronchopneumology, psychiatry.

The Headquarter and main R&D site are located in Italy.

Rottapharm has recently acquired the global German pharmaceutical Group Madaus Pharma and today the Rottapharm|Madaus Group has subsidiaries or direct commercial operations throughout Europe and in the vast majority of Middle East, Asia (excluding Japan) and Central/South America countries.

Currently Rottapharm's main products include: the original Glucosamine Sulfate EU prescription product that paved the way for several nutraceutical glucosamines with yet unsurpassed clinical expertise in the development of Disease Modifying Drugs in Osteoarthritis; a line of matrix transdermal delivery systems for HRT and CVD; and others out of a list of 19 new drugs derived from over 300 patents. Moreover, the Group has recently implemented a line of effective and successful nutraceuticals for dyslipidemias, women's health, inflammation, and entered the area of personal care that includes a line of leading products in intimate hygiene/paediatric/skin care and in which the company is ranked as the sixth largest in the world market.

Finally, with the acquisition of Madaus, Rottapharm's expertise in the genito-urinary area has been strongly improved. Important synergies have been identified in this area, where the Rottapharm|Madaus Group is benefiting not only the ongoing clinical research activities but also the presence on the market of leading products such as Spasmo Urgenin (relief of painful urinary symptoms) and Spasmolyt/Uraplex/Regurin (overactive bladder), and Uralyt (urolithiasis).

    1. Data on file, Rotterpharm 2009.
    2. Pietzko A, et al, Eur J Clin Pharmacol 1994;47:337-343.
    3. Lobenberg R, et al Eur J Biopharm 2000; 50: 3-12.
    4. Herberg KW. Med Weit 1999;50:217-222.
    5. Napier C, Gupta P Neurourol Urodyn 2002;21: A 444
    6. Ikeda K, et al. Naunyn-Schmiedberg's Arch Pharmacol 2002; 366:97-103.
    7. Staskin D, Harnett M, Curr Urolo Rep 2004;5:423-6.
    8. National Collaborating Centre for Women's and Children's Health.
       Urinary incontinence: the management of urinary incontinence in women.
       October 2006.
    9. Staskin D, et al. J Urol 2007;178:978-984.
    10. Dmochowski R, et al. Urology 2008;71:449-454.
    11. Schladitz-Keil, et al.Arzneim-Forsch/Drug Res 1986;36(I)Nr.6:948-987
    12. Sandage B, et al. Poster Pres. ICS and IUGA Joint Meeting, Paris
        2004. Abstract 584.
    13. Regurin XL Prescribing Information.
    14. NICE clinical guideline - Urinary incontinence - the management of
        urinary incontinence in women CG40, 2006
    15. Regurin XL 60 MG - Summary of Product Characteristics Available at

    Billy Hargan
    General Manager, UK
    Speciality European Pharma Ltd
    Direct: +44(0)207-421-7408
    Mobile: +44(0)7872-600022

    Hugh McKinney
    Ruder Finn, UK
    Direct: +44(0)20-7462-8942
    Mobile: +44(0)7961-323810

SOURCE Speciality European Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Approves Valcyte(R) (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants
2. Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
3. New Data Presented at AUAs Annual Conference Prove GELNIQUE(TM) (oxybutynin chloride) 10% gel is an Effective, Safe Option for Female Overactive Bladder (OAB) Patients
4. MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine
5. Announces New Free Report - International Trade Opportunity: The Brazilian Acai Berry
6. Arcadia HealthCares DailyMed(TM) Signs Deal with Comfort Keepers(R), A Leading Provider of In-Home Care
7. Patents Issued Covering Stable Tablet Formulation and Once Daily Dosing Regimen for Kuvan
8. Intense Daily Workout May Keep Cancer at Bay
9. Life after chemotherapy: Daily tasks, quality of life may be affected, MU researcher finds
10. U.S. Census Bureau Daily Feature for July 21
11. FertilityAuthority Introduces E-Newsletter, The Daily Shot
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Baptist Medical Center Jacksonville has ... the only hospital in the region providing what is known as the world’s ... patients were revealed recently at a medical conference and published in The New ...
(Date:12/1/2015)... TX (PRWEB) , ... December 01, 2015 , ... Dr. ... of Vitenas Cosmetic Surgery, has been named by MedEsthetics magazine as the Best Single ... of the best among the many elite aesthetic physicians honored by the industry publication. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments ... to decreases in utilization of hospital and nonhospital care, according to a recent study ... Benchmarks for Louisiana, 16th Edition , found medical payments per claim with more than ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... the 1980s we have seen vast improvements in scientific research and discoveries, leading ... strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s cross-platform ...
(Date:12/1/2015)... ... , ... It’s official: Tattoo taboo is a thing of the past. One ... (a whopping one in three aged 18 to 25 is inked). As tattoos transition ... ink. In fact, RealSelf , the world’s largest community for learning and sharing ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , December 1, 2015 ... Contraceptive Injectables, Topical Contraceptives, Male Condoms, Female ... Vaginal Rings, Contraceptive Diaphragms, Contraceptive Sponges, Non-Surgical ... Size, Share, Growth, Trends and Forecast 2014 ... Transparency Market Research (TMR).The report states that ...
(Date:12/1/2015)... 1, 2015  InCarda Therapeutics, Inc. (InCarda), a privately-held ... therapies for cardiovascular conditions via the inhalation route, today ... Australia . InCarda is planning to ... Australia in the first half of 2016. ... centers in Adelaide and Melbourne.  ...
(Date:12/1/2015)... 2015 ) ... Alert Systems/Personal Emergency Response System (PERS) Market by ... Forecas" report to their offering. --> ... the "Medical Alert Systems/Personal Emergency Response System ... Geography - Global Forecas" report to their ...
Breaking Medicine Technology: